Journal Article DKFZ-2017-05778

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses.

 ;  ;  ;  ;  ;  ;  ;  ;

2016
Nature Publishing Group New York, NY

Molecular therapy 3, 16018 - () [10.1038/mtm.2016.18]
 GO

This record in other databases:  

Please use a persistent id in citations: doi:

Abstract: Oncolytic viruses (OVs) are unique anticancer agents based on their pleotropic modes of action, which include, besides viral tumor cell lysis, activation of antitumor immunity. A panel of diverse viruses, often genetically engineered, has advanced to clinical investigation, including phase 3 studies. This diversity of virotherapeutics not only offers interesting opportunities for the implementation of different therapeutic regimens but also poses challenges for clinical translation. Thus, manufacturing processes and regulatory approval paths need to be established for each OV individually. This review provides an overview of clinical-grade manufacturing procedures for OVs using six virus families as examples, and key challenges are discussed individually. For example, different virus features with respect to particle size, presence/absence of an envelope, and host species imply specific requirements for measures to ensure sterility, for handling, and for determination of appropriate animal models for toxicity testing, respectively. On the other hand, optimization of serum-free culture conditions, increasing virus yields, development of scalable purification strategies, and formulations guaranteeing long-term stability are challenges common to several if not all OVs. In light of the recent marketing approval of the first OV in the Western world, strategies for further upscaling OV manufacturing and optimizing product characterization will receive increasing attention.

Classification:

Contributing Institute(s):
  1. Translationale Onkologie (G100)
  2. Tumorvirologie (F010)
  3. Onkolytische Adenoviren (F110)
Research Program(s):
  1. 316 - Infections and cancer (POF3-316) (POF3-316)

Appears in the scientific report 2016
Database coverage:
Medline ; Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version) ; DOAJ ; DOAJ Seal ; NCBI Molecular Biology Database
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Public records
Publications database

 Record created 2017-11-23, last modified 2024-02-28


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)